<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311164</url>
  </required_header>
  <id_info>
    <org_study_id>Steno Tech Explore</org_study_id>
    <nct_id>NCT04311164</nct_id>
  </id_info>
  <brief_title>Steno Tech Explore: A Study of Insulin Pump Users With Type 1 Diabetes</brief_title>
  <official_title>Steno Tech Explore: A Multisite Exploratory Study of People With Type 1 Diabetes on Insulin Pump Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is part of an overarching study being conducted in Denmark at Steno&#xD;
      Diabetes Center Copenhagen (SDCC) and Nordsjællands Hospital Hillerød (NOH), Steno Tech, that&#xD;
      aims to develop and ultimately, in a randomized controlled trial (RCT), test approaches that&#xD;
      can assist people with type 1 diabetes in obtaining optimal outcomes using CSII. Through a&#xD;
      large-scale, questionnaire-based online survey enriched with data from national registers,&#xD;
      this sub-study contributes to this overarching aim by exploring the importance of individual&#xD;
      differences across a wide range of factors, including demographic, socioeconomic, health&#xD;
      status, psychosocial and preference structures, for optimal use of CSII in people with type 1&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See attached protocol for a detailed description.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Glycated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>13 years (from 2008 (beginning of register) to present)</time_frame>
    <description>Information on HbA1c in mmol/mol will be extracted from national registers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other diabetes-relevant biomarkers</measure>
    <time_frame>13 years (from 2008 (beginning of register) to present)</time_frame>
    <description>Biomarkers included at the regular diabetes 'check-up' other than HbA1c including hemoglobin, eGFR, UACR, cholesterol total, HDL, LDL, VLDL, triglycerides and TSH will be extracted from national registers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General diabetes and insulin pump-specific behavior</measure>
    <time_frame>1 day (measured at one time point only, i.e., at the survey completion date for each participant)</time_frame>
    <description>Measured with single items in the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological well-being</measure>
    <time_frame>1 day (measured at one time point only, i.e., at the survey completion date for each participant)</time_frame>
    <description>Measured with the WHO5 questionnaire scale in the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes distress</measure>
    <time_frame>1 day (measured at one time point only, i.e., at the survey completion date for each participant)</time_frame>
    <description>Measured with the Type 1 Diabetes Distress (T1-DDS) questionnaire scale in the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia anxiety</measure>
    <time_frame>1 day (measured at one time point only, i.e., at the survey completion date for each participant)</time_frame>
    <description>Measured with the Hypoglycemia Fear Survey short-form (HFS-SF) questionnaire scale in the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technology-specific satisfaction</measure>
    <time_frame>1 day (measured at one time point only, i.e., at the survey completion date for each participant)</time_frame>
    <description>Measured with the Insulin Device Satisfaction Survey (IDSS) and the Glucose Monitoring Satisfaction Survey (GMSS) questionnaire scales in the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Educational, time and risk preferences</measure>
    <time_frame>1 day (measured at one time point only, i.e., at the survey completion date for each participant)</time_frame>
    <description>Measured with single items in the survey and experimental tasks</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">770</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Steno Tech Survey Respondents</arm_group_label>
    <description>A cohort of individuals with type 1 diabetes treated with CSII at either SDCC or NOH participating in the Steno Tech Survey.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Type 1 Diabetes Population</arm_group_label>
    <description>A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca. 25.000 individuals).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire-based survey</intervention_name>
    <description>The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.</description>
    <arm_group_label>Steno Tech Survey Respondents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention given.</intervention_name>
    <description>No intervention was given.</description>
    <arm_group_label>General Type 1 Diabetes Population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of two groups/cohorts:&#xD;
&#xD;
          1. Steno Tech Survey Respondents: A cohort of individuals with type 1 diabetes treated&#xD;
             with CSII at either Steno Diabetes Center Copenhagen or Nordsjaellands Hospital&#xD;
             Hilleroed participating in the Steno Tech Survey.&#xD;
&#xD;
          2. General Type 1 Diabetes Population: A cohort consisting of the entire population of&#xD;
             people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort&#xD;
             (ca. 25.000 individuals).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        The Steno Tech Survey Repondents group:&#xD;
&#xD;
          -  Adult (18+ years)&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Insulin pump user&#xD;
&#xD;
          -  Danish-speaking&#xD;
&#xD;
        The General Type 1 Population group:&#xD;
&#xD;
          -  Adult (18+ years)&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Signe Schmidt</investigator_full_name>
    <investigator_title>MD, PhD, Researcher</investigator_title>
  </responsible_party>
  <keyword>continous subcutaneous insulin infusion</keyword>
  <keyword>clinical outcomes</keyword>
  <keyword>psychological outcomes</keyword>
  <keyword>educational aspects</keyword>
  <keyword>preferences</keyword>
  <keyword>inequality and inequity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT04311164/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

